DIRS.INFO The most relevant business & tech news

☆ Sandoz owners are banking on margin cure
▼ + stars: | 2023-10-04 | by ( ) www.reuters.com time to read: +2 min

LONDON, Oct 4 (Reuters Breakingviews) - Sandoz’s (SDZ.S) investors are giving CEO Richard Saynor the benefit of the doubt. Shares in the generics drug maker, which $217 billion pharma giant Novartis (NOVN.S) has finally managed to spin off, started to trade in Zurich on Wednesday. There was a risk that Novartis investors, who have long called for a sale or spinoff, would quickly dump the new Sandoz shares. At current market prices, Sandoz is worth nearly $11 billion, or $14.4 billion once net debt is added in. For now, Novartis investors seem to believe Sandoz’s treatment may be effective.

Persons: Richard Saynor, Sandoz, Aimee Donnellan, Lisa Jucca, Streisand Neto Organizations: Reuters, Novartis, Sandoz, Hikma Pharmaceuticals, X, Brookfield pounces, Temasek, Thomson Locations: Zurich, That’s

☆ 'Good value, low risk, high quality': BofA names top Europe stocks to beat a recession
▼ + stars: | 2023-07-25 | by ( Lucy Handley | ) www.cnbc.com time to read: +2 min

Bank of America has named multiple European "top stocks" it says are of "good value, low risk" and "high quality." All of them turned up on "recession screens" for July, in a market BofA described as a being in a recession style cycle. The euro zone entered recession in the first quarter of the year, according to economic data released last month. Energy companies the bank named include Shell , German company EON and Italian firm Enel . During recession cycles, investors have benefited from being overweight on value stocks rather than growth stocks, as well as on stocks with strong balance sheets and lower risk, BofA added, citing research based on a testing period between 1992 and 2003.

Persons: EON, Reckitt, BofA, — CNBC's Michael Bloom Organizations: of America, Roche, Novartis, Sanofi, GSK, Volvo, Benz, Ferrari . Energy, Shell, Unilever, Lysol, Hikma Pharmaceuticals, Auto Locations: Howden

☆ U.S. seeks new suppliers of highly used cancer drug methotrexate in short supply
▼ + stars: | 2023-06-09 | by ( ) www.cnbc.com time to read: +2 min

The U.S. Food and Drug Administration said on Friday it is seeking new suppliers to ease shortages of methotrexate, one of the most commonly used cancer drugs, building on its push to shore up two other scarce chemotherapy medicines. An FDA spokesperson told Reuters the agency is looking for temporary importation options for the drug, which has been in shortage since March. Methotrexate is an injected drug used to treat a wide variety of cancers ranging from acute lymphoblastic leukemia in children, breast cancer, lung cancer, bone cancers and certain types of head and neck cancers, according to the National Cancer Institute. Last week, the FDA said it was looking for additional temporary suppliers for two other cancer chemotherapies, cisplatin and carboplatin. According to the American Society of Health-System Pharmacists, suppliers with methotrexate injections in shortage or on back order include Accord Healthcare, Fresenius Kabi, Pfizer , Teva and Hikma Pharmaceuticals .

Persons: Methotrexate, cisplatin, China's, Senators Gary Peters, Debbie Stabenow, Fresenius Kabi Organizations: . Food, Drug Administration, FDA, Reuters, National Cancer Institute, Pharmaceutical, U.S, Senators, Intas Pharmaceuticals, Healthcare, American Society of Health, System Pharmacists, Accord Healthcare, Pfizer, Teva, Hikma Pharmaceuticals Locations: United States, India, U.S

☆ UBS says disinflation is on the way — and shares 8 global stocks to play it
▼ + stars: | 2022-11-14 | by ( Ganesh Rao | ) www.cnbc.com time to read: +2 min

After a year of double-digit inflation in many countries, UBS is now forecasting "sharp" disinflation in 2023. The bank screened for stocks it expects to be positively impacted in such an environment. The table below shows two stocks across four regions that UBS says will benefit the most from disinflation. British healthcare companies Genus and Hikma Pharmaceuticals ranked highly among the stocks UBS says will benefit from disinflation in the United Kingdom. "The negative payoff from getting our disinflation call wrong is large," strategists led by Arend Kapteyn warned.

One of the most commonly used antibiotics in the country, amoxicillin, is in short supply, federal health officials say. The department also listed a shortage for an oral powder. It wasn't immediately clear what prompted the shortage or how long it could last. A spokesman for the FDA previously said a number of factors can cause drug shortages, including manufacturing and quality problems, delays and discontinuations. The American Society of Health-System Pharmacists, which maintains a database of drug shortages, last reported shortages from the companies Monday.

Pharmacies across the United States are reporting shortages of one of the most widely used antibiotics, raising concerns that the medication will be in short supply for the upcoming winter season. Three key amoxicillin manufacturers — Hikma Pharmaceuticals, headquartered in the United Kingdom; Sandoz, based in Switzerland; and Teva Pharmaceutical Industries Ltd., headquartered in Israel — are reporting shortages of the antibiotic, according to the American Society of Health-System Pharmacists, which maintains a database of drug shortages. Because amoxicillin is an antibiotic, it is not used to treat infections caused by viruses, such as Covid, the flu or RSV (respiratory syncytial virus). Pharmacists said they are worried if the shortage lingers through the winter, when infections can surge and antibiotic use typically increases. “However, there are a number of factors that can cause or contribute to drug shortages that are out of the FDA’s control.

Search resuls for: "Hikma Pharmaceuticals"

6 mentions found